Crucell NV has agreed to buy Swedish biotech company SBL Vaccin AB for Euro 39.4 million in cash from 3i Group and SEB. The deal is expected to close on Thursday. www.crucell.comwww.sblvaccines.se
Nearly there!
We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case
it’s been delivered there.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.